AIR-DOCTOR
31.5.2022 12:02:03 CEST | Business Wire | Press release
Medical care and travel startup Air Doctor has secured $20M in funding for scaling the company globally. This second round of investment capitalizes on the worldwide influx in travelers after the Covid-19 pandemic and will enable the company to enter its next phase of growth.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220531005013/en/
Air Doctor, raised $20 million, led by Lightspeed Venture Partners. Joining this round are Vintage Investment Partners and Munich Re Ventures, alongside The Phoenix , one of Israel's leading insurance providers, as well as Kamet Ventures , which led the company’s previous round.
Founded by Jenny Cohen Derfler, Efrat Sagi Ofir, Yam Derfler and Yegor Kurbachev, Air Doctor has previously raised $10.9 million since its launch in 2018. The startup currently employs over 60 people based in Israel and Europe.
The Air Doctor platform connects travelers who fall ill abroad with local private doctors through an easy-to-use mobile and web app. Air Doctor’s outpatient medical network covers 74 countries and includes over 20,000 medical professionals who provide either in-person or telemedicine consultations. Following the Covid-19 pandemic, medical assistance while traveling has become a major concern for travelers and insurers alike. Air Doctor’s platform provides the assurance travelers need to enjoy their trip.
In addition to bringing on board more developers to work on product customization, Air Doctor will use the new investment to hire new employees and open additional offices internationally. The company also has plans to expand the product and marketing teams, and the vetted medical professional network, particularly in the US and Europe.
In 2020, the COVID-19 outbreak brought the world to a standstill, with unprecedented and unanticipated consequences affecting people's lives and global economies. The travel and tourism sector experienced a severe economic slowdown as a result of stringent quarantine regulations and travel restrictions.
“As the world emerges from COVID-19, people have resumed travel, with a greater demand for suitable travel insurance and digital solutions. The pandemic has forced the industry to reassess local medical treatment available for travelers. Today, travelers testing positive for the Coronavirus will be able to seek medical care in the local communities they are in rather than in hospitals.” said Jenny Cohen Derfler, CEO and Founder of Air Doctor. “Air Doctor has become one of the fastest-growing startups, with tens of thousands registered users and many more accessing the network worldwide. Today the company offers a unique and distinctive digital product with almost no competition worldwide.” Said CEO Cohen Derfler
According to the World Economic Forum’s recent survey , the travel industry is expected to fully recover by 2024. Additionally, many countries may mandate travel insurance coverage. These two factors will create a dramatic surge in the need for better travel insurance. Furthermore, insurers facing travelers’ demands are seeking to expand their offer of digital, physical and online healthcare coverage to provide an improved customer experience and reduce claim costs.
“Building our partner and investor network will be an ongoing endeavor, as well as boosting our R&D capabilities and end-user activation. We’re also on the lookout to find new team members who are keen to join an exciting startup that is expanding globally,” said Efrat Sagi-Ofir, Co-Founder and Chief Revenue Officer of Air Doctor.
“Air Doctor addresses a major pain point for the health and travel insurance industry, and Lightspeed is excited to lead the company’s new $20 million funding round. Air Doctor continues to prove itself as an innovator in travel health by digitizing a significant aspect of the travel experience,” said Yoni Cheifetz, Partner at Lightspeed. “
About Air Doctor
Launched in Israel in 2018, Air Doctor is a startup that connects travelers seeking medical attention with local doctors whilst abroad through their intuitive mobile and desktop app. With a global network of over 20,000 medical professionals across 2,000 cities in 74 countries, Air Doctor provides travelers with peace of mind and aims to make healthcare accessible to everyone, everywhere.
About Lightspeed
Lightspeed Venture Partners is a multi-stage venture capital firm focused on accelerating disruptive innovations and trends in the Enterprise, Consumer and Health sectors. Over the past two decades, the Lightspeed team has backed hundreds of entrepreneurs and helped build more than 400 companies globally, including Snap, Nest, Nutanix, AppDynamics, MuleSoft, OYO, Guardant, Affirm, and GrubHub. Lightspeed and its affiliates currently manage $10.5B across the global Lightspeed platform, with investment professionals and advisors in Silicon Valley, Israel, India, China, Southeast Asia, and Europe. www.lsvp.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220531005013/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 14:05:00 CEST | Press release
Trained on more than 13,000 patient studies, novel system significantly outperforms existing models by up to 35% A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is d
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 14:00:00 CEST | Press release
New research shows that brands aligned with emotionally heightened moments in live sports can improve ad effectiveness Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The r
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 14:00:00 CEST | Press release
Precemtabart tocentecan (Precem-TcT) is investigated as a potential first-in-class anti-CEACAM5 ADC, for the treatment of metastatic CRC (mCRC) CEACAM5 is overexpressed in the majority of colorectal tumors (~90%), and requires no patient selection Significant unmet need remains for clinically meaningful innovation in colorectal cancer (CRC), the second leading cause of cancer death worldwide Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer
Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 13:00:00 CEST | Press release
Randomized controlled trial will evaluate both symptom progression and underlying biology Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early
Unpack ’26 sommerrejsetrends: Flere vælger indenlandske rejser, når de tænker mere bevidst over deres rejsevalg21.5.2026 12:35:00 CEST | Pressemeddelelse
Rejsebranchens førende databrevne trendrapport lancerer sin første sommerudgave nogensinde – Unpack ’26 Summer: The Trends in Travel I dag har Hotels.com udgivet Unpack ’26 Summer: The Trends in Travel, den nyeste udgave af virksomhedens førende trendrapport i rejsebranchen, som viser, hvordan rejseadfærd former sommerens rejsevalg. Efterspørgslen på indenlandske rejser præger sommerens ferieplanlægning. Interessen på sociale medier for indenlandske ferier er globalt steget med 77% sammenlignet med sidste år, og 44% af danske rejsende planlægger en indenlandsk rejse denne sommer*. Fra store sportsbegivenheder og koncerter til rejser inspireret af film og tv bygger Unpack ’26 Summer på indsigter fra den årlige hovedrapport Unpack ’26: The Trends in Travel™ for at fremhæve, hvor rejsende tager hen denne sommer. HHver tendens bygger på førstehåndsdata fra Hotels.com® kombineret med indsigter fra rejsende og overvågning af sociale medier. “Denne sommer bliver der stadig rejst – men på nye
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom